PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$58.93

23 Sep
2021

1.010

OPEN

$58.10

1.74%

HIGH

$59.27

132,522

LOW

$57.88

TARGET
$54.49 -7.5% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY20
Actual		 FY21
Actual		 FY22
Forecast		 FY23
Forecast
EPS (cps) xxx 29.6 42.0 xxx
DPS (cps) xxx 15.0 19.0 xxx
EPS Growth xxx 33.4% 41.8% xxx
DPS Growth xxx 25.0% 26.7% xxx
PE Ratio xxx N/A 138.3 xxx
Dividend Yield xxx N/A 0.3% xxx
Div Pay Ratio(%) xxx 50.6% 45.2% xxx

Dividend yield today if purchased 3 years ago: 1.27%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.26

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 09/09 - 8c (100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx29.6
DPS All xxxxxxxxxxxxxxx15.0
Sales/Revenue xxxxxxxxxxxxxxx67.9 M
Book Value Per Share xxxxxxxxxxxxxxx78.4
Net Operating Cash Flow xxxxxxxxxxxxxxx39.0 M
Net Profit Margin xxxxxxxxxxxxxxx45.45 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Assets xxxxxxxxxxxxxxx27.89 %
Return on Equity xxxxxxxxxxxxxxx43.49 %
Return on Total Capital xxxxxxxxxxxxxxx57.75 %
Capex xxxxxxxxxxxxxxx7.7 M
Capex % of Sales xxxxxxxxxxxxxxx11.33 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx25.3 M

Return on Assets

Return on Equity

Return on Total Capital

Capex

Capex % of Sales

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

19/08/2021

5

Reduce

$54.49

-7.53%

The FY21 results for Pro Medicus were lower than Morgans and consensus expectations though strong earnings (EBITDA) margins were a standout. A 735 basis points (bps) improvement exceeded the assumed 335bps uplift.

The broker lifts its price target to $54.49 from $49.69 and retains its Reduce rating and advocates holders with outsized positions trim into price strength. While FY21 margins continued to expand, they are expected to be less pronounced in FY22 as in-person trade shows and conference costs recommence.

The analyst highlights the signing of research collaboration agreements with NYU Langone Health and Mayo Clinic. In addition, the February FDA approval for the company’s Breast Density AI Algorithm is considered positive.

FORECAST
Morgans forecasts a full year FY22 dividend of 19.00 cents and EPS of 42.00 cents.
Morgans forecasts a full year FY23 dividend of 22.00 cents and EPS of 49.00 cents.
Access Stockbroker Research History >

PME STOCK CHART

FNArena News on PME

1
Rudi’s View: Telstra, Iress, NextDC And That Grand Delusion

Sep 23 2021 - Rudi's View
2
Australian Broker Call *Extra* Edition – Sep 15, 2021

Sep 15 2021 - Daily Market Reports
3
Heroes Of The Reporting Season

Sep 01 2021 - Weekly Reports
4
Rudi’s View: BHP, Dividends, And Breville Group

Aug 26 2021 - Rudi's View
5
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals

Latest Medical Equipment & Devices News

1
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
2
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
3
Breakout For Cochlear

Aug 10 2021 - Technicals
4
Will ResMed’s Market Share Gains Last?

Aug 09 2021 - Australia
5
Treasure Chest: Has Nanosonics Been Too Successful?

Jul 08 2021 - Treasure Chest
6
Opportunity For ResMed Following Philips Recall

Jun 16 2021 - Australia
7
Treasure Chest: How Much Covid Impact For Nanosonics?

May 13 2021 - Treasure Chest
8
Who Will Be The Next Pro Medicus?

May 13 2021 - Weekly Reports
9
New Product, Patient Growth Key To ResMed

May 03 2021 - Australia
10
Growth For ResMed Despite Challenges

Feb 01 2021 - Australia